CambridgeSoft Corp., a provider of software and services for discovery, analysis and collaboration to the life sciences and chemical industries, academia and government, announced completion of a private equity investment by Health Evolution Partners and a follow-on investment by Goldman Sachs Group, Inc. (GS)
CambridgeSoft noted that, in connection with this investment, Adam Grossman will represent Health Evolution Partners on its Board of Directors.
Health Evolution Partners Chairman David Brailer, said, "Pharmaceutical and biotechnology companies increasingly rely on information technology to create new therapies. We are enthusiastic to be part of CambridgeSoft..,"
The Cambridge, Massachusetts-based company added that Raheel Zia, vice president of Goldman Sachs, will continue serving on its Board, based upon the New York-based financial services firm's original investment in 2008.
Michael Tomasic, President and CEO of CambridgeSoft, stated, "I am delighted to work with Health Evolution Partners to expand CambridgeSoft. Their involvement underscores a continuing commitment to innovation, high growth and financial excellence for the company and its future of serving the life sciences industry's growing need for outsourcing of software and service for research IT."
For comments and feedback: editorial@rttnews.com